India drug regulator meets to discuss AstraZeneca vaccine -sources

PUBLISHED: Wed, 30 Dec 2020 12:34:24 GMT

NEW DELHI, Dec 30 (Reuters) – Experts at India’s drug regulator were meeting on Wednesday to consider approving an AstraZeneca/Oxford coronavirus vaccine for emergency use after Britain became the first country to do so, two sources with knowledge of the matter said.

A representative of India’s Central Drugs Standard Control Organization (CDSCO) declined to reveal the agenda of the meeting but said its minutes would be uploaded on its website within hours.

Sources earlier told Reuters the CDSCO was likely to approve the vaccine this week after its local manufacturer, Serum Institute of India (SII), submitted additional trial data.

SII, the world’s biggest producer of vaccines, has already stockpiled about 50 million doses, enough for 25 million people.

It welcomed the UK approval.

“This is great and encouraging news,” Chief Executive Adar Poonawalla said in a statement. “We will wait for the final approval from Indian regulators.”

India wants to start administering the shots starting next month and is also considering emergency use authorisation applications for vaccines made by Pfizer Inc with Germany’s BioNTech and by India’s Bharat Biotech.

India, which has the world’s second highest number of COVID-19 infections in the world after the United States, plans to inoculate 300 million people in the next six to eight months and the affordable Oxford vaccine is its biggest hope.

Though the Indian government has not yet signed a purchase agreement with SII, the company says it will focus on its home market first, and then exports, mainly to South Asian countries and Africa. (Reporting by Nigam Prusty and Krishna N. Das; editing by Jason Neely)

(c) Copyright Thomson Reuters 2020. Click For Restrictions –

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.